Lacrimal Duct Stent Tube Market 2022 Industry Research, Segmentation, Key Players Analysis and Forecast to 2029

There has been higher preference for bicanalicular lacrimal duct stent tube over its monocanalicular counterpart, attributing to the former’s high success rate, suitability for stenting in older patients, and better clinical outcomes. Moreover, increasing prevalence of retina-related conditions, primarily imperforation of nasolacrimal duct, epiphora both in infants and adults, and conditions necessitating dacryocystorhinostomy are other factors responsible for propelling revenue growth of the lacrimal duct stent tube market.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9649

Consistent efforts towards diagnosis and management of lacrimal duct obstruction with enhanced success rate, minimally invasive lacrimal surgery, and better clinical outcomes, and increasing product awareness among ophthalmologist are factors augmenting growth prospects for the lacrimal duct stent tube market.

Key Takeaways – Lacrimal Duct Stent Tube Market Study

• Bicanalicular lacrimal duct stent tube is expected to contribute three fourth of revenue share in the lacrimal duct stent tube market owing to its high success rate in stent placement.
• Hospitals captured maximum share of the lacrimal duct stent tube market owing to highest patient footfall followed by ophthalmic clinics.
• Attributed to growing patient pool for retinal diseases, especially due to premature births, contributed to the dominance of North America in the lacrimal duct stent tube market.
• Increasing awareness for availability of the treatment for nasolacrimal duct stent obstruction among caregivers of prematurely born babies and increasing number of skilled professionals are expected to drive growth of the lacrimal duct stent tube market in East Asia.

Manufacturers Emphasizing Advanced Product Development

Numerous organizations are focusing on new product development for lacrimal duct stent tube. In June 2019, FCI Ophthalmic offered a complete line of BIKA stents namely, BIKA, BIKA for DCR, and Infant BIKA covering a range of sizes that will benefit most of the congenital nasolacrimal duct obstruction (CNLDO) and dacryocystorhinostomy (DCR) cases.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-9649

Know More About Lacrimal Duct Stent Tube Market Report

Future Market Insights brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each segment from 2014 to 2029. The global lacrimal duct stent tube market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on lacrimal duct stent tube market on basis of product type (monocanalicular lacrimal duct stent tube, bicanalicular lacrimal duct stent tube), and end user (hospitals, ophthalmic clinics, ambulatory surgical centers), across seven major regions.

FREQUENTLY ASKED QUESTIONS ABOUT LACRIMAL DUCT STENT TUBE MARKET

Which region is expected to lead in terms of revenue in lacrimal duct stent tube market?

North America remains most lucrative region in terms of revenue and is anticipated to grow at an impressive rate during the forecast period. India, China, and Brazil are expected to be targeted geographies for incremental opportunity for regional and major players.

Which product segment would be most attractive for investments?

Bicanalicular lacrimal duct stent tube emerged as the attractive segment by product type representing 3/4th of revenue share in the lacrimal duct stent tube market. Easier usability, improved patient compliance, material compatibility of bicanalicular lacrimal duct stent with patient without causing any adverse reaction are key pointers in driving growth of the segment.

Which end users would contribute maximum revenue during the forecast period?

Hospitals are expected to hold half of the total market revenue share during the forecast period. Ophthalmic clinics are anticipated to be second most attractive segment owing to increase in number of surgeries and number of cases related to nasolacrimal duct obstruction.

Who are the major players in the lacrimal duct stent tube market?

FCI Ophthalmics, Kaneka Corporation are the key players in the lacrimal duct stent tube market. New product development is the key strategy folowed by these players. Effective marketing strategy among ophthalmologists and cost effectivity are other criterias that manufacturers are competing on.

What complications associated with stent tubes are hampering market growth?

Corneal abrasion is the most common complication encountered during treatment procedure. To overcome this complication, manufacturers in the lacrimal duct stent tube market are focusing on altering the length of stent, material used for manufacturing, etc. The process still has risk of complications, considering the age group in which stenting is carried out. These complications may hamper the potential growth of the market.

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/9649